This company listing is no longer active
EPE Stock Overview
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Epizyme, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$4.90 |
| 52 Week Low | US$0.35 |
| Beta | -0.42 |
| 1 Month Change | -2.74% |
| 3 Month Change | 178.43% |
| 1 Year Change | -69.20% |
| 3 Year Change | -88.07% |
| 5 Year Change | -88.07% |
| Change since IPO | -92.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| EPE | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -1.2% | -0.8% |
| 1Y | -69.2% | -15.8% | 1.0% |
Return vs Industry: EPE underperformed the German Biotechs industry which returned -2.5% over the past year.
Return vs Market: EPE underperformed the German Market which returned -20.5% over the past year.
Price Volatility
| EPE volatility | |
|---|---|
| EPE Average Weekly Movement | 23.5% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EPE's share price has been volatile over the past 3 months.
Volatility Over Time: EPE's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 250 | Grant Bogle | www.epizyme.com |
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others.
Epizyme, Inc. Fundamentals Summary
| EPE fundamental statistics | |
|---|---|
| Market cap | €241.38m |
| Earnings (TTM) | -€202.60m |
| Revenue (TTM) | €51.70m |
4.7x
P/S Ratio-1.2x
P/E RatioIs EPE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPE income statement (TTM) | |
|---|---|
| Revenue | US$53.01m |
| Cost of Revenue | US$20.28m |
| Gross Profit | US$32.73m |
| Other Expenses | US$240.47m |
| Earnings | -US$207.73m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 61.75% |
| Net Profit Margin | -391.88% |
| Debt/Equity Ratio | -1,148.4% |
How did EPE perform over the long term?
See historical performance and comparison